What is HC Wainwright's Forecast for Belite Bio Q3 Earnings?

Key Points

• HC Wainwright has revised down its Q3 2025 earnings per share estimate for Belite Bio to ($0.53), down from a previous forecast of ($0.49).
• Belite Bio's stock currently holds a "Buy" rating with a price target of $100.00, despite recent downgrades from other analysts.
• The company reported a Q2 earnings miss with EPS of ($0.50), falling short of the consensus estimate by ($0.03).

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Free Report) - Equities research analysts at HC Wainwright reduced their Q3 2025 earnings per share estimates for Belite Bio in a report issued on Tuesday, August 12th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.53) per share for the quarter, down from their prior estimate of ($0.49). HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio's Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.01) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($2.03) EPS.

Belite Bio (NASDAQ:BLTE - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.03). During the same quarter in the prior year, the business earned ($0.31) earnings per share.

Other equities research analysts have also issued research reports about the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Belite Bio in a research note on Thursday, May 15th. Wall Street Zen downgraded Belite Bio from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $96.67.

Belite Bio Stock Performance

NASDAQ BLTE traded down $2.35 during trading hours on Thursday, hitting $66.63. 44,722 shares of the company's stock were exchanged, compared to its average volume of 49,584. The business's 50 day moving average is $62.77 and its 200-day moving average is $61.64. Belite Bio has a 12-month low of $43.70 and a 12-month high of $86.53. The firm has a market capitalization of $2.12 billion, a P/E ratio of -42.99 and a beta of -1.49.

Institutional Trading of Belite Bio

A number of institutional investors and hedge funds have recently made changes to their positions in BLTE. GAMMA Investing LLC lifted its position in shares of Belite Bio by 43.3% during the 1st quarter. GAMMA Investing LLC now owns 1,849 shares of the company's stock worth $122,000 after purchasing an additional 559 shares during the last quarter. EverSource Wealth Advisors LLC bought a new stake in shares of Belite Bio in the 2nd quarter valued at approximately $147,000. BNP Paribas Financial Markets bought a new stake in shares of Belite Bio in the 4th quarter valued at approximately $155,000. XTX Topco Ltd grew its stake in shares of Belite Bio by 30.9% in the 4th quarter. XTX Topco Ltd now owns 7,062 shares of the company's stock valued at $446,000 after purchasing an additional 1,668 shares during the period. Finally, Marshall Wace LLP bought a new stake in Belite Bio during the 2nd quarter worth approximately $547,000. Institutional investors and hedge funds own 0.53% of the company's stock.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.